Background-Pulmonary hypertension (PH) is associated with poor prognosis in patients with severe aortic stenosis. The aim of this multicenter study was to describe clinical outcome after transcatheter aortic valve implantation.
D egenerative aortic stenosis (AS) is the most common acquired valvular heart disease in Western countries. 1, 2 It is found in 2% to 3% of individuals aged ≥65 years and in ≤5% of individuals aged >80 years. Severe pulmonary hypertension (PH; systolic pulmonary artery pressure [sPAP] ≥60 mm Hg) is found in 15% to 20% of these patients and, if untreated, is of poor prognosis. [3] [4] [5] In patients undergoing surgical aortic valve replacement (AVR), PH has been found to be an independent predictor of major adverse cardiovascular events, significantly increasing mortality. [3] [4] [5] [6] [7] [8] Although AVR in the presence of PH is associated with higher complications rates, potential benefits outweigh the risks of surgery. Transcatheter aortic valve implantation (TAVI) has emerged as an alternative to AVR in high-risk patients with contraindications for surgery. 9 The Placement of Aortic Transcatheter Valves (PARTNER) A trial confirmed that TAVI was not associated with poorer outcome than surgery in high-risk patients, with 24.2% 1-year mortality versus 26.8% after AVR (P=0.44) 10 ; TAVI is thus now increasingly performed worldwide. Previous studies showed that severe PH increased mortality in TAVI as in surgical AVR. 3, [11] [12] [13] In 2010, a prospective national TAVI registry was initiated in France. The FRANCE 2 Registry reflects real-life experience, including consecutive patients from all centers in France. Results for patient characteristics and outcomes have been published recently, 14 reporting 97% procedural success, 10% 30-day, and 24% 1-year mortality. A total of 89.5% of surviving patients were asymptomatic or only mildly symptomatic. The present study sought to assess the prognostic value of PH in patients with severe AS managed by TAVI, based on the FRANCE 2 Registry.
Methods

Patient Population
A total of 3195 consecutive patients were enrolled in the FRANCE 2 Registry between January 2010 and October 2011 in 34 centers. Institution review board approval of the French Ministry of Health was obtained. This prospective registry included all symptomatic adults (NYHA [New York Health Association] functional class ≥II) requiring TAVI for severe AS and with high risk for AVR surgery because of comorbidity or contraindications (porcelain aorta, chestwall deformity, chest radiation, or other coexisting conditions not included in risk scores). High surgical risk was defined by a Society of Thoracic Surgeons score >10% and logistic European System for Cardiac Operative Risk Evaluation >20%.
The study population comprised patients whose pre-TAVI sPAP had been reported. They were divided into 3 groups according to the absence of PH (sPAP, <40 mm Hg: group I), mild-to-moderate PH (sPAP, 40-59 mm Hg: group II), or severe PH (sPAP, ≥60 mm Hg: group III). sPAP was estimated by transthoracic echocardiography, based on the simplified Bernoulli equation describing the relationship between the velocity and peak pressure gradient of tricuspid regurgitation: (peak pressure gradient)=4×(tricuspid regurgitation velocity); sPAP can be estimated from this equation, taking into account right atrial pressure, based on inferior vena cava diameter and respiratory variation: sPAP=tricuspid regurgitation peak pressure gradient+estimated right atrial pressure.
Description of Device and Procedures
Each center could choose to implant one of the commercially available valves: the balloon-expandable Edwards (SAPIEN or SAPIEN XT) valve or the self-expandable CoreValve (or CoreValve Accutrack); the approach was transarterial or transapical, depending on peripheral access. Both types of devices were used in 30 centers, and the Edwards SAPIEN alone in 4. There was no prespecified choice of access; choice between general and local anesthesia for transarterial implantation was left up to the individual team. Transarterial access was performed either percutaneously or after surgical cut-down, whereas transapical access was obtained by anterior mini-thoracotomy. Valve implantation was preceded by balloon dilation.
Study End Points
The primary end point was death, defined as mortality from all causes after prosthesis insertion, at 30 days and 1 year. Secondary outcomes comprised procedural success, cardiovascular event-free survival at 1 year, procedure-related events, change from baseline NYHA functional class at 30 days and 1-year post TAVI, and change from baseline sPAP at 30 days and 1 year. Cardiovascular events included all-cause mortality, myocardial infarction, and major stroke. Procedural success was defined as successful vascular access, correct device positioning in the proper anatomic location, and intended prosthetic heart valve performance (aortic valve area >1.2 cm 2 and mean aortic valve pressure gradient <20 mm Hg or peak velocity <3 m/s, without moderate or severe prosthetic valve aortic regurgitation). Procedure-related events were defined as those occurring during or as a direct result within 24 hours after TAVI and were classified as cardiological (myocardial infarction, ventricular or supraventricular arrhythmia, complete atrioventricular block, necessity of pacemaker implantation, heart failure, and tamponade), vascular (hemorrhage, arterial thrombosis/dissection/rupture, and aorta dissection), hemorrhagic (with or without vital risk, tamponade), neurological (minor or major stroke), valvular (valve migration, acute coronary obstruction, aortic annulus rupture, and aortic valve insufficiency), and conversion to surgery or other (renal failure with or without dialysis, sepsis). 15
Statistical Analysis
Continuous variables following a normal distribution are presented as mean±SD and otherwise expressed as median (Q1-Q3 or min to max). Categorical variables are presented as counts and percentages. We used F test through generalized linear model to compare distribution of continuous variables across level of sPAP defined as the absence of PH (sPAP, <40 mm Hg: group I), mild-to-moderate PH (sPAP, 40-59 mm Hg: group II), or severe PH (sPAP, >60 mm Hg: group III). Cumulative incidences of clinical events at follow-up were assessed with the Kaplan-Meier method. Patients lost to follow-up were considered at risk until the date of last contact, at which point they were censored. Stepwise logistic regression analysis, including all baseline variables correlating with sPAP at a P value of <0.1 on univariate analysis, was used to determine independent predictors of early (30-day) mortality; results are presented as odds ratios with 95% confidence intervals (CIs). Cox stepwise multivariate analysis, including all baseline variables correlating with sPAP at a P value of <0.1 on univariate analysis, was used to determine independent predictors of overall and late (>30 days ≤1 year) mortality. Results are presented as hazard ratios (HRs) with 95% CI. The validity of the proportionality assumption was verified for all covariates by a visual examination of the log (minus log) curves and a test based on Schoenfeld residuals. All reported P values are 2-sided; the significance threshold was set at P<0.05. All data were processed using the SAS version 9.3 release.
Results
Baseline Characteristics
Pre-TAVI sPAP was reported in the database for 2435 of the 3195 patients (76.2%). Group 1 (sPAP, <40 mm Hg: no PH) included 845 patients (34.7%), group 2 (sPAP, 40-59 mm Hg: mild-to-moderate PH) included 1112 patients (45.7%), and group 3 (sPAP, ≥60 mm Hg: severe PH) included 478 patients (19.6%). Median delay between echographic sPAP measurement and TAVI procedure was 5 days.
WHAT IS KNOWN
• Severe pulmonary hypertension has been found to be associated with major adverse cardiovascular events and mortality in patients with severe aortic stenosis undergoing surgical aortic valve replacement.
• Transcatheter aortic valve implantation has emerged as an alternative to aortic valve replacement in highrisk patients with aortic stenosis and contraindications to surgery.
WHAT THE STUDY ADDS
• In patients with severe pulmonary hypertension, transcatheter aortic valve implantation led to substantial reduction in pulmonary artery pressure.
• Procedural and 30-day outcomes after transcatheter aortic valve implantation did not differ between patients with and without elevated pulmonary artery pressure, but 1-year survival was worse in those with pulmonary hypertension.
Baseline clinical and echographic characteristics of each group are presented in Table 1 . Mean age in all groups was 83±7 years. In group III patients, mean sPAP was 65 mm Hg (range, 60-110); they were more symptomatic (84.9% NYHA functional class III or IV), had higher logistic European System for Cardiac Operative Risk Evaluations (mean, 28.3%), and more frequent history of aortic valve replacement surgery and balloon valvuloplasty. They also showed greater prevalence of atrial fibrillation, diabetes mellitus, and abdominal aortic aneurysm. Rates of hypertension, coronary artery disease, renal failure, previous stroke, and chronic obstructive pulmonary disease were similar in all 3 groups, but group III patients had significantly less history of bypass graft surgery. Mean left ventricular ejection fraction (LVEF) in group III was 49±15 mm Hg, lower than in the other groups (P<0.0001); aortic valve areas were smaller and mitral regurgitation (MR) was more frequent. Mean aortic valve pressure gradient was similar in the 3 groups. The median follow-up duration of our patients was 157 days in group I (interquartile range, 34-267), 137 days in group II (interquartile range, 33-248), and 170 days in group III (interquartile range, 35-311).
Procedural Characteristics
There were no significant intergroup differences in access route or choice of device (SAPIEN versus CoreValve). Implantation approach was most frequently transfemoral (73.9%, 75.3%, 76.8%, respectively, per group; P=0.2), followed by transapical, subclavian, or transaortic or transcarotid. Edwards SAPIEN devices were equally frequent in each group (64.2%, 69.3%, and 68.3%, respectively per group; P=0.2), as were CoreValve devices (35.2%, 30.6%, and 31.7%, respectively; P=0.2). Procedural characteristics are summarized in Table 2 .
Primary End Points
At 1 year, mortality rates from all causes on Kaplan-Meier analysis were higher in groups II and III than in group I (primary end point). One-year mortality was 22% (95% CI, 18%-26%) in group I (sPAP, <40 mm Hg), 28% (95% CI, 24%-32%) in group II (sPAP, 40-59 mm Hg), and 28% (95% CI, 23%-34%) in group III (sPAP, >60 mm Hg); P=0.032. Thirty-day to 1-year post-TAVI mortality was also higher in patients with PH (groups II and III). In contrast, 30-day mortality rates did not significantly differ between groups: 10% in group I, 10% in group II, and 11% in group III; P=0.5. Kaplan-Meier survival curves for the 3 groups are shown in Figure 1 .
On univariate analysis, mild-to-moderate PH, severe PH, LVEF <30%, mean aortic valve gradient, aortic valve area, history of balloon valvuloplasty, aortic abdominal aneurysm, peripheral artery disease, coronary artery disease, bypass graft surgery, and aortic valve surgery were significantly related to 1-year all-cause mortality. On Cox regression multivariate analysis, mortality was found to be affected adversely by mild-to-moderate PH (HR, 1.22; 95% CI, 0.96-1.54) and severe PH (HR, 1.33; 95% CI, 1.01-1.75), severe left ventricular dysfunction with LVEF <30% and abdominal aortic aneurysm.
In overall population, median PAP value was statistically higher, but moderately, (45 versus 43; P=0.001) in patients who died when compared with those who survived (Table 3 ).
Secondary End Points
One-year cardiovascular event-free survival was statistically similar in group I compared with that in groups II and III (Figure 2) . At 1 year, death from all causes, myocardial infarction, or stroke occurred in 28% of patients in group I, 33% in group II (P=0.2), and 33% in group III (P=0.1). Events at 30 days and at 1 year are shown in Table 4 .
Procedural success was similar regardless of sPAP: 94.2% in group I, 95% in group II, and 95.4 in group III (P=0.6). Patients with mild/moderate to severe PH (groups II and III) did not have more procedure-related events than those without (group I; P=0.8; Table 2 ). The most common events were cardiological (≈35%), hemorrhage (≈25%), and vascular (≈23%). There was also no difference in valve prosthesis complications, such as valve migration, aortic rupture, or acute coronary occlusion.
At follow-up, NYHA functional class showed improvement in each group (Table 5) . At baseline (pre-TAVI), 72.5% of group I, 77.1% of group II, and 84.9% of group III were NYHA class III/IV, compared with 7.9%, 13%, and 13.8%, respectively, at first follow-up (median, 37 days; P<0.0001), and 9.1%, 11.4%, and 13.2%, respectively, at last follow-up (median, 237 days; P<0.0001).
Decreased sPAP was observed in groups II and III at last follow-up (P=0.01); median sPAP in group I was 32 mm Hg at baseline, 35 mm Hg at 30 days, and 34 mm Hg at 1 year, compared with group II (45, 40, and 40 mm Hg, respectively) and group III (65, 49, and 45 mm Hg; Table 6 ). Change in post-TAVI PA pressure is shown in a scatter plot depicting sPAP before and early after TAVI (Figure 3 ). Prevalence of ≥2 postprocedural paravalvular leaks immediately and at first follow-up did not significantly differ according to sPAP (P=0.8 and P=0.2). Likewise, rates of grade 3 to 4 postprocedural MR were similar at first follow-up in all groups: 1.5% in group I, 2.4% in group II, and 2.3% in group III (P=0.5; Table 6 ).
Discussion
This large prospective study points to the following conclusions: in patients undergoing TAVI for severe AS, PH from 40 mm Hg and especially severe PH with sPAP >60 mm Hg is an independent predictor of 1-year mortality (although the incidence of major adverse cardiovascular events is not affected), but it does not influence quality of functional improvement at 1 year. Severity of PH does not affect procedural risk or 30-day mortality after TAVI. Right-heart catheterization is the reference measurement of PAP. However, using an invasive method for a routine assessment of pulmonary artery pressures is not standard practice in patients with valvular heart disease and is not in accordance with European Society of Cardiology/European Association of Cardio-Thoracic Surgery guidelines on the management of valvular heart disease. 16 Echocardiographic assessment of pulmonary pressures is a surrogate measurement, but which has the advantage of being noninvasive and therefore easier to use in large series as in the present registry.
In the FRANCE 2 population, PH (sPAP, >40 mm Hg) was present in 65.3% of patients and severe PH (sPAP, >60 mm Hg) in 19.6%; these rates are close to those reported in the literature for patients with severe AS. 8, [17] [18] [19] The significance of high PAP in patients with AS remains unclear, the most important mechanism is a correlation between increased PAP and LV diastolic dysfunction, with passive transmission of increased LV end-diastolic and left atrial pressures to the pulmonary arteries. 3, 4, 8, 19, 20 In addition to increased left atrial and LV diastolic pressures, PH is influenced by the degree of MR. 21 In the present study, patients with severe PH had more frequent AF (P<0.0001) and grade 3 or 4 MR (P=0.0003) at baseline. By first follow-up, the incidence of grade 3 or 4 MR was similar in all groups, suggesting an early improvement in MR severity in patients with PH, because of pressureoverload reduction.
In routine practice, surgical risk, assessed on Society of Thoracic Surgeons score and European System for Cardiac Operative Risk Evaluation, has been used to predict 30-day mortality after cardiac surgery. 22, 23 In the present study, mean European System for Cardiac Operative Risk Evaluation, which takes several parameters into account, including presence and level of PH, was higher in group III (mean, 28.3%) than in groups I and II (15.6% and 19.7%, respectively). The mean Society of Thoracic Surgeons score, which does not consider PH at all, was comparable in all 3 groups (10.1%, 9.8%, and 9.8%, respectively; P=0.3). There were no differences in procedural success or 30-day mortality between groups, suggesting that PH is not a predictive factor of poor early outcome. Likewise, Tamburino et al, 11 in 663 consecutive patients who underwent TAVI with the CoreValve device, did not identify severe PH as an independent predictor of 30-day mortality. In contrast, PH has early clinical implications after surgical AVR: Melby et al, 24 in 1080 patients who underwent AVR for primary aortic valve stenosis, found significantly higher 30-day mortality in patients with PH (9.3% versus 5.4%; P=0.18). Severe PH was also an independent predictor of early mortality in the study of Di Eusanio et al 25 of 2256 patients managed by AVR (odds ratio, 5; 95% CI, 1.1-5.9).
However, several studies also have shown that PH has a negative impact on late outcome in patients undergoing AVR, and preoperative PH is clearly recognized today as a strong indicator of late mortality after AVR. [3] [4] [5] [6] [7] [8] The present study shows that PH was also a predictive factor of 1-year mortality after TAVI; on multivariate analysis, mild-to-moderate and especially severe PH emerged as an independent factor of mortality (HR, 1.22; 95% CI, 0.96-1.54 and HR, 1.33; 95% CI, 1.01-1.75, respectively). Tamburino et al 11 likewise reported that severe PH correlated with overall mortality (HR, 3.21), but they did not study the role of mild-to-moderate PH. Rodés-Cabau et al, 12 in 339 patients treated by TAVI, showed that severe PH was a predictor of cumulative late mortality (HR, 1.88) at a median follow-up of 8 months. Gotzmann et al 13 also reported PH to be significantly related to all-cause mortality after TAVI, as was reduced LVEF (as in the present study), with severe systolic LV impairment (LVEF <30%) further identified as an independent predictor of mortality at 1 year. In the present study, cardiovascular event-free survival at 1 year was 72% in group I, 67% in group II (P=0.2), and 67% in group III (P=0.1); likewise, stroke occurred in 2.7%, 2%, and 2.5% and myocardial infarction in 1.4%, 1.3%, and 1.05% of cases, respectively (ie, with no significant difference). Thus, PH from sPAP ≥40 mm Hg appeared as a predictor of death from any cause but not of major adverse cardiovascular events. We observed in this work a higher mortality from both cardiovascular and noncardiovascular causes in groups with PH, but the differences do not reach the statistical significance for cardiovascular and noncardiovascular causes. The only statistical significant difference concerns the total mortality. So, we can conclude that severe PH affects global mortality, with a nonsignificant statistical increase of both cardiovascular and noncardiovascular mortality.
Association between post-TAVI sPAP and death was estimated in 1223 patients with postimplant sPAP measurement and an available date of measurement. Among those 1223 patients, 79 (6.5) died within 1 year. Postimplant sPAP was statistically associated with overall survival both as a continuous measure (HR for 20 mm Hg change 2. Previous studies demonstrated rapid improvement in systolic, diastolic, and mean PAP after AVR, resulting in improvement in clinical outcome. 18, 26, 27 The present study found a decrease in PH after TAVI, associated with net functional benefit. Ben-Dor et al 3 showed a significant and sustained decrease in pulmonary pressure up to 1 year after TAVI, comparable with that seen after AVR. In the present study, patients with severe pre-TAVI PH were more symptomatic: 72.5% of group I, 77.1% of group II, and 84.9% of group III were in NYHA functional classes ≥III (P<0.0001). At last followup, NYHA classification showed clear improvement, with 9.1% of group I, 11.4% of group II, and 13.2% of group III in classes ≥III (P<0.0001); improvement was greater in patients with severe PH (P<0.0001) and was early and durable. This is of particular importance in the elderly, for whom the aim of intervention is essentially to improve quality of life.
Limitations
The follow-up of our patients is short, the median delay of follow-up is 178 days and only 25% of patients have a follow-up of ≥340 days. This is the main limitation of the present study. On Cox regression multivariate analysis, the impact of severe PH on global mortality with a 95% CI of 1.01 to 1.75, less than expected, could be related to this relative short follow-up. With such a low 30-day mortality rate (10%), we acknowledged that type II error should be considered; a post hoc power calculation showed that a size group ≈400 patients gives a high power (97%) to detect a 2.0 increased risk for mortality but indeed power is reduced to 53% for detecting a 1.5 increased risk.
Data on complications are probably less robust than survival because they were reported by each participating centers and were not independently adjudicated in a central core laboratory.
The FRANCE 2 Registry was a national registry with all the procedures included during 22 months. We should recognize that among patients with missing sPAP value, we cannot distinguish those with unmeasured sPAP from those with unmeasurable sPAP.
Nevertheless, we compared characteristics of patients included in our study (n=2435) with those not included because of unknown sPAP before the TAVI procedure. No difference has been documented between both groups. PAP values were reported for only 76.2% of patients, owing to the noninvasive estimation by Doppler echocardiography using tricuspid regurgitation velocity, which is not always present or detectable. Echocardiography uses an estimation of PAP, whereas the catheterization method uses direct measurement; the estimation method also may have decreased the overall accuracy of the PAP measurements.
Conclusions
These findings suggest that the heart team should take account of PH in pre-TAVI risk assessment. Our results suggest that a pulmonary hypertension, even severe, associated with symptomatic AS should not lead to exclude patients from TAVI, which is a reasonable option in patients with pulmonary hypertension. PH increases the procedural risk and is not only associated with a higher 1-year mortality risk but also with a higher net functional benefit. Median first and last FU was 37 and 237 days, respectively. FU indicates follow-up; NYHA, New York Health Association; PAP, pulmonary artery pressure; and TAVI, transcatheter aortic valve implantation. Median first and last FU was 37 and 237 days, respectively. Comparisons for first and last FU systolic PAP were adjusted for baseline value. FU indicates follow-up; PAP, pulmonary artery pressure; and TAVI, transcatheter aortic valve implantation. Figure 3 . Scatter plot depicting systolic pulmonary artery pressure (sPAP) before and early after transcatheter aortic valve implantation (TAVI).
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